The Federal Antimonopoly Service (FAS) of Russia has agreed on prices for the domestic generic drug Rivastigmine-ET (rivastigmine). The department’s press service has reported that the cost of the foreign reference drug Exelon has been reduced by an average of 11% compared to the registered prices.
“The FAS has agreed on prices for a drug used in the treatment of Alzheimer’s disease and dementia in Parkinson’s disease,” the statement says. It is clarified that the price for a package of Rivastigmine-ET of 30 patches at a dosage of 4.6 mg will be 1,362 rubles. At the same time, the cost of a similar dosage of the reference drug is registered at 1,518 rubles.
